Description: Author reported on sessions she attended at September 2009 NAIC meeting, including much information on the Valuation Manual.

Description: A high-level overview of the recent release of the update to the illustration practice notes, or IPNs.

Description: Legislation introduced in Florida senate to ban sale of Industrial Life and greatly restrict sales of other Small Face Amount Policies, SFAPs.

Description: This article talks about assets and liabilities as they related to Sarbanes-Oxley legislation. From Small Talk Newsletter, November 2005, Issue No. 25.

Description: Article summarizing two conference calls from late 2011 on regulatory issues of interest to smaller insurance companies. From Small Talk Newsletter, Issue 37, January 2012.

Description: Small companies face numerous challenges and opportunities when developing supplemental health insurance products. This is particularly true because of the competitive nature of these products and the innovations happening in the supplemental health market. This article explores the challenges regarding rating, the volatile regulatory environment, product flexibility, and distribution. In addition, the article identifies competitive advantages that small companies may have in the supplemental health market.

Description: The article provides an introduction to some of the key limitations that the Internal Revenue Code imposes on business uses of life insurance, focusing on the limitations under Section 264(a) on business deductions for premiums and interest expenses related to life insurance, the similar limitations under Section 264(f) for unrelated interest expenses of businesses that own life insurance, the limitations under Section 101(j) on the excludability of death benefits under employer-owned life insurance contracts, and the recently-enacted rules for life settlement transactions.

Description: Update on tax regulatory and legislative developments of relevance to life actuaries

Description: Join us for an insightful webcast as we delve into the far-reaching implications of the recent Supreme Court decision to overturn Chevron deference. This landmark ruling, which previously granted federal agencies significant leeway in interpreting ambiguous statutes, is set to reshape the landscape of healthcare policy.

Description: Develop a better understanding of specialty drug trends and their increasing healthcare costs for more than the past decade by attending this webcast. With the introduction of price competition, you will see changes in the market for biosimilar products and patent-protected drugs. For example, the drug Humira will be gaining 10 biosimilar competitors in 2023. Alone, Humira can represent over 20% of total pharmacy spend for health plans. Join us and discover how price competition is a turning point for the pharmaceutical industry and will define its direction for the next decade.